PREDICT-GBM: Platform for Robust Evaluation and Development of Individualized Computational Tumor Models in Glioblastoma

Abstract

Glioblastoma is the most prevalent primary brain malignancy, distinguished by its highly invasive behavior and exceptionally high rates of recurrence. Conventional radiation therapy, which employs uniform treatment margins, fails to account for patient-specific anatomical and biological factors that critically influence tumor cell migration. To address this limitation, numerous computational models of glioblastoma growth have been developed, enabling generation of tumor cell distribution maps extending beyond radiographically visible regions and thus informing more precise treatment strategies. However, despite encouraging preliminary findings, the clinical adoption of these growth models remains limited. To bridge this translational gap and accelerate both model development and clinical validation, we introduce PREDICT-GBM, a comprehensive integrated pipeline and dataset for modeling and evaluation. This platform enables systematic benchmarking of state-of-the-art tumor growth models using an expert-curated clinical dataset comprising 255 subjects with complete tumor segmentations and tissue characterization maps. Our analysis demonstrates that personalized radiation treatment plans derived from tumor growth predictions achieved superior recurrence coverage compared to conventional uniform margin approaches for two of the evaluated models. This work establishes a robust platform for advancing and systematically evaluating cutting-edge tumor growth modeling approaches, with the ultimate goal of facilitating clinical translation and improving patient outcomes.